Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
Covid-19 Vaccines Cost-Effectiveness Analysis: A Scenario for Iran Publisher



Vaezi A1 ; Meysamie A2, 3
Authors

Source: Vaccines Published:2022


Abstract

COVID-19 vaccines are supposed to be critical measure for ending the pandemic. Govern-ments had to decide on the type of vaccine to provide for their population. In this decision-making process, cost-effectiveness analysis is considered a helpful tool. This study is a cost-effectiveness analysis utilized to calculate the incremental cost per averted disability-adjusted life year (DALY) by vaccination compared to no vaccination for different COVID-19 vaccines. The incremental cost-effectiveness ratio (ICER) for a vaccination with COVID-19 vaccines was estimated at 6.2 to 121.2 USD to avert one DALY and 566.8 to 10,957.7 USD per one death. The lowest and highest ICERs belong to Ad26.COV2.S and CoronaVac, respectively. Considering the scenario of Iran, vaccines that are recommended include ad26.cov2.s, chadox1-S, rAd26-S + rAd5-S, and BNT162b2 in the order of recommendation. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Related Docs
View other Related Docs
1. Covid-19 Vaccine Boosters: The Good, the Bad, and the Ugly, Vaccines (2021)
2. Efficacy and Safety of an Inactivated Virus-Particle Vaccine for Sars-Cov-2, Biv1-Coviran: Randomised, Placebo Controlled, Double Blind, Multicentre, Phase 3 Clinical Trial, BMJ (2023)
3. Covid-19 Infection Risk Following Elective Arthroplasty and Surgical Complications in Covid-19-Vaccinated Patients: A Multicenter Comparative Cohort Study, Arthroplasty Today (2022)
Experts (# of related papers)
View all Related Experts
Vahid Shaygannejad (2)
Atefeh Vaezi (2)
Other Related Docs
4. Importance of the Covid-19 Vaccine Booster Dose in Protection and Immunity, Vaccines (2022)
5. Acute Cns Demyelination in a Subject With Cerebellar Ataxia Following the First Dose of Covid-19 Vaccine; a Case Report, Human Vaccines and Immunotherapeutics (2021)
6. Cost-Effectiveness Analysis of the Introduction of Hpv Vaccination of 9-Year-Old-Girls in Iran, Value in Health Regional Issues (2018)
7. Incidence of Bell's Palsy After Coronavirus Disease (Covid-19) Vaccination: A Systematic Review and Meta-Analysis; [Incidencia De La Paralisis De Bell Despues De La Vacunacion Contra La Covid-19: Una Revision Sistematica Y Un Metanalisis], Neurologia (2024)
8. Immunogenicity of Covid-19 Vaccines in Patients With Diabetes Mellitus: A Systematic Review, Frontiers in Immunology (2022)
9. New Variants of Covid-19 (Xbb.1.5 and Xbb.1.16, the “Arcturus”): A Review of Highly Questioned Concerns, a Brief Comparison Between Different Peaks in the Covid-19 Pandemic, With a Focused Systematic Review on Expert Recommendations for Prevention, Vaccination, and Treatment Measures in the General Population and At-Risk Groups, Immunity, Inflammation and Disease (2024)
10. Cardiovascular Complications of Sars-Cov-2 Vaccines: An Overview, Cardiology and Therapy (2022)
11. The Effect of Covid-19 Vaccination on Reducing the Risk of Infection, Hospitalization, and Death in Isfahan Province, Iran, Iranian Journal of Public Health (2022)
12. Safety of Sinopharm Vaccine for People With Multiple Sclerosis: Study of Adverse Reactions and Disease Activity, Multiple Sclerosis and Related Disorders (2022)
13. Vaccine-Associated Complications: A Comparative Multicenter Evaluation Among Dental Practitioners and Dental Students—Which Candidate Vaccine Is More Safe in Sars Cov Ii, Gam-Covid-Vac (Sputnik V), Chadox1 Ncov-19 (Astrazeneca), Bbv152 (Covaxin), or Bbibp-Corv(Sinopharm)?, Maxillofacial Plastic and Reconstructive Surgery (2022)
14. Cost-Effectiveness and Cost-Utility Analysis of Otc Use of Simvastatin 10 Mg for the Primary Prevention of Myocardial Infarction in Iranian Men, DARU, Journal of Pharmaceutical Sciences (2015)
15. Cost-Utility Analysis of Combination Medical Therapies in Chronic Coronary Syndrome: A Comparative Study Using Real-World and Patient-Level Data From Iran, BMJ Open (2025)
16. Cost-Effectiveness and Cost-Utility Analysis of Type-2 Diabetes Screening in Pharmacies in Iran, Research in Pharmaceutical Sciences (2023)
17. A Population-Based and Symptom-Based Covid-19 Prevalence Survey, Journal of Education and Health Promotion (2023)
18. Efficacy and Safety of a Protein-Based Sars-Cov-2 Vaccine: A Randomized Clinical Trial, JAMA Network Open (2023)
19. Immunization Coverage of Children Aged 24–35 Months in the Islamic Republic of Iran: A National Cluster Coverage Survey; [Couverture Vaccinale Des Enfants Ages De 24 a 35 Mois En Republique Islamique D'iran: Enquete Nationale De Couverture Par Sondage En Grappes], Eastern Mediterranean Health Journal (2022)
20. Sars-Cov-2 Antibody Seroprevalence in the General Population and High-Risk Occupational Groups Across 18 Cities in Iran: A Population-Based Cross-Sectional Study, The Lancet Infectious Diseases (2021)